Ulcerative Colitis Clinical Trial
Official title:
Implementing a Multimodal RCT Intervention to Improve the Transition of Patients With Crohn's Disease From Pediatric to Adult Care
Verified date | April 2024 |
Source | The Hospital for Sick Children |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Transition in care is defined as the "purposeful and planned movement of adolescents and young adults with a chronic medical condition from pediatric to adult-oriented healthcare systems/care providers." Currently, there is no Level 1 evidence of an intervention to improve the care of transitioning adolescents and young adults (AYAs) with inflammatory bowel disease (IBD). The development of a transition program using a biopsychosocial approach will improve the standards for healthcare delivery to transitioning IBD patients. This is a protocol for a structured randomized controlled trial (RCT) to assess the efficacy and impact of a multimodal intervention focused on improving patient function, transition readiness and outcomes among AYA patients with IBD being cared for at pediatric centers in Canada. Methods: This multi-center RCT is a type 1 hybrid effectiveness-implementation trial to evaluate effectiveness of the intervention and how it can be implemented more widely after the trial. We will include patients aged 16.0 to 17.5 years. The intervention program consists of 4 core components: 1) individualized assessment, 2) transition navigator, 3) virtual patient skills-building with a focus on building resilience, self-management and self-efficacy, and 4) a virtual structured education program. The control group will undergo standard-of-care defined by each participating center. The primary outcome will be the IBD Disability Index, a validated measure to assess patient functioning. Secondary outcomes include transition readiness, anxiety and depression scales, and health service utilization rates. Additionally, we will identify the effectiveness of an evidence-based implementation approach and related barriers and facilitators for the intervention program. Discussion: The type 1 hybrid effectiveness-implementation design will allow us to develop a feasible, sustainable, and acceptable final intervention model. The intervention will consist of modules that can be accessed in an online, virtual platform. The implementation will not depend on individual hospital resources, allowing centralization of interventions and funding. The authors anticipate that the main study limitation will relate to study subjects not completely adhering to every component of the intervention, which will be evaluated and addressed using the implementation science approach.
Status | Active, not recruiting |
Enrollment | 90 |
Est. completion date | December 31, 2025 |
Est. primary completion date | July 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 17 Years |
Eligibility | Inclusion Criteria: - Aged 16-17.5 years - Diagnosed with IBD diagnosed using standard criteria - Ability to speak/read English at a functional (Grade 8) level - Intention to reside in Canada after transfer to adult care - Ability to use a smartphone or personal computer for the virtual intervention Exclusion Criteria: - Do not speak English fluently - Intention to leave Canada after graduation from high school |
Country | Name | City | State |
---|---|---|---|
Canada | Children's Hospital of Eastern Ontario | Ottawa | Ontario |
Canada | The Hospital for Sick Children | Toronto | Ontario |
Canada | BC Children's Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
The Hospital for Sick Children | Crohn's and Colitis Canada, The Canadian Children Inflammatory Bowel Disease Network: A Partnership with the CH.I.L.D. Foundation, The CH.I.L.D. Foundation - Children with Intestinal & Liver Disorders, The Leona M. and Harry B. Helmsley Charitable Trust |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | IBD Disability Index (IBD-DI) | Ordinal variable that measures participant functioning as the primary outcome. IBD-DI was selected as a validated measure of overall disability, functioning, and health. The primary outcome will be measured 3 years after enrollment. | 3 years | |
Secondary | Transition Readiness Assessment Questionnaire (TRAQ) | Transition Readiness | 3 years | |
Secondary | Transition Readiness Assessment Questionnaire (TRAQ) | Transition Readiness | Up to 24 months (at time of transfer to adult care) | |
Secondary | Transition Success Scores (TSS) | Transition Readiness | 3 years | |
Secondary | Transition Success Scores (TSS) | Transition Readiness | Up to 24 months (at time of transfer to adult care) | |
Secondary | Pediatric IBD INTERMED | Biopsychosocial Risk Profile | 3 years | |
Secondary | Pediatric IBD INTERMED | Biopsychosocial Risk Profile | Up to 24 months (at time of transfer to adult care) | |
Secondary | IBD-KID2 | Disease-related knowledge | 3 years | |
Secondary | IBD-KID2 | Disease-related knowledge | Up to 24 months (at time of transfer to adult care) | |
Secondary | IBDQ-32 | Quality of life | 3 years | |
Secondary | IBDQ-32 | Quality of life | Up to 24 months (at time of transfer to adult care) | |
Secondary | IBD Self-Efficacy Scale - Adolescent (IBD-SES-A) | Self-Efficacy | 3 years | |
Secondary | IBD Self-Efficacy Scale - Adolescent (IBD-SES-A) | Self-Efficacy | Up to 24 months (at time of transfer to adult care) | |
Secondary | Physician Global Assessment (PGA) | Physician assessment of disease activity | 3 years | |
Secondary | Physician Global Assessment (PGA) | Physician assessment of disease activity | Up to 24 months (at time of transfer to adult care) | |
Secondary | Fecal calprotectin | Measure of gut inflammation | 3 years | |
Secondary | Modified Harvey-Bradshaw Index (HBI) for Crohn's disease | Disease activity in Crohn's disease patients | 3 years | |
Secondary | Modified Harvey-Bradshaw Index (HBI) for Crohn's disease | Disease activity in Crohn's disease patients | Up to 24 months (at time of transfer to adult care) | |
Secondary | Pediatric Ulcerative Colitis Activity Index (PUCAI) | Disease activity in ulcerative colitis patients | 3 years | |
Secondary | Pediatric Ulcerative Colitis Activity Index (PUCAI) | Disease activity in ulcerative colitis patients | Up to 24 months (at time of transfer to adult care) | |
Secondary | Emergency department visit after 18th birthday (yes/no) | Health services utilization | 3 years | |
Secondary | Number of emergency department visits after 18th birthday | Health services utilization | 3 years | |
Secondary | Hospitalization after 18th birthday (yes/no) | Health services utilization | 3 years | |
Secondary | Number of outpatient visits to a gastroenterologist after 18th birthday | Health services utilization | 3 years | |
Secondary | IBD Disability Index (IBD-DI) | Ordinal variable that measures participant functioning as the primary outcome. IBD-DI was selected as a validated measure of overall disability, functioning, and health. | Up to 24 months (at time of transfer to adult care) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |